



May 26, 2026

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Subject: Outcome of the Board Meeting held on May 26, 2026

Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 read with Regulation 30 and other applicable provisions of the Listing Regulations, as amended, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. on Tuesday, May 26, 2026 at 11:10 a.m. and concluded at 02:30 p.m., has, *inter-alia*, approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2026, and took on record the Auditor's reports with unmodified opinion on the audited financial results.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the copy of Audited Financial Results for the quarter and financial year ended March 31, 2026, Auditor's reports with unmodified opinion on the audited financial results and a declaration from the Chief Financial Officer confirming the unmodified opinion of the statutory auditors on the aforesaid audited financial results.

The above-mentioned documents will also be available on the Company's website www.jubilantingrevia.com

We request you to take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary
Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657

Walker Chandiook & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram- 122002
India
T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Report on Consolidated Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

Opinion


1. We have audited the accompanying consolidated annual financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), including SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025.
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditor on separate audited financial statements of the subsidiary, as referred to in paragraph 12 below, the Statement:
 - (i) includes the annual financial results of the entities listed in Annexure 1;
 - (ii) presents financial results in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations; and
 - (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group and its associates for the year ended 31 March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group and its associates, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditor in terms of their report referred to in paragraph 12 of the Other Matters section below, is sufficient and appropriate to provide a basis for our opinion.

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune



Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Responsibilities of Management and Those Charged with Governance for the Statement

4. The Statement has been prepared on the basis of the consolidated annual financial statements and has been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit and other comprehensive income, and other financial information of the Group including its associates in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) of the Listing Regulations including SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group and its associates, covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group and its associates, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
5. In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associates, are responsible for assessing the ability of the Group and of its associates, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group and of its associates.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;



Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

- Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates to cease to continue as a going concern;
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
 - Obtain sufficient appropriate audit evidence regarding the financial statements of the entities or business activities within the Group and its associates, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors. For the other entity included in the Statement, which has been audited by the other auditor, such other auditor remains responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion.
9. We communicate with those charged with governance of the Holding Company and such other entities included in the Statement, of which we are the independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
11. We also performed procedures in accordance with circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

12. We did not audit the annual financial statements of a subsidiary included in the Statement whose financial statements reflects total assets of ₹ 1,061 lakhs as at 31 March 2026, total revenues of ₹ Nil, total net profit after tax of ₹ 33 lakhs, total comprehensive income of ₹ 23 lakhs, and net cash inflows of ₹ Nil for the year ended on that date, as considered in the Statement. These annual financial statements have been audited by other auditor whose audit report have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the audit report of such other auditor and the procedures performed by us as stated in paragraph 11 above.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

13. The Statement also includes the Group's share of net loss after tax of ₹ 18 lakhs, and total comprehensive loss of ₹ 18 lakhs for the year ended 31 March 2026, in respect of an associate, based on their annual financial information, which have not been audited by their auditor. These financial information have been furnished to us by the Holding Company's management. Our opinion, in so far as it relates to the amounts and disclosures included in respect of aforesaid associate, is based solely on such unaudited financial information. In our opinion, and according to the information and explanations given to us by the management, these financial information are not material to the Group.

Our opinion is not modified in respect of this matter with respect to our reliance on the financial information certified by the board of directors.



Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

14. The Statement includes the consolidated financial results for the quarter ended 31 March 2026, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani

Partner

Membership No. 517440



UDIN: 26517440XVCRTL7953

Place: Gurugram

Date: 26 May 2026

Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Annexure 1

List of entities included in the Statement

| S. No | Name | Relationship with the Holding Company |
|-------|--|---|
| 1 | Jubilant Infrastructure Limited | Subsidiary |
| 2 | Jubilant Agro Science Limited | Subsidiary |
| 3 | Jubilant Ingrevia (USA) Inc. (formally known as Jubilant Life Science (USA) Inc.) | Subsidiary |
| 4 | Jubilant Life Sciences NV | Subsidiary |
| 5 | Jubilant Ingrevia International Pte. Limited (formally known as Jubilant Life Sciences International Pte. Limited) | Subsidiary |
| 6 | Jubilant Life Sciences (Shanghai) Limited | Subsidiary |
| 7 | Jubilant Ingrevia Employee Welfare Trust | Subsidiary |
| 8 | Remidex Pharma Private Limited | Subsidiary (with effect from 30 March 2026) |
| 9 | Mister Veg Foods Private Limited | Associate |
| 10 | AMP Energy Green Fifteen Private Limited | Associate |
| 11 | O2 Renewable Energy XVIII Private Limited | Associate (with effect from 25 April 2025) |



Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)
CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Consolidated Audited Financial Results for the Quarter and Year Ended 31 March 2026

(₹ in Lakhs)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|-----------|---|---------------|---------------|---------------|---------------|---------------|
| | | 31 March | 31 December | 31 March | 31 March | 31 March |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | | 2026 | 2025 | 2025 | 2026 | 2025 |
| 1 | Revenue from operations | | | | | |
| | a) Sales/Income from operations | 116605 | 103972 | 103816 | 434485 | 412367 |
| | b) Other operating income | 1260 | 1119 | 1310 | 4322 | 5394 |
| | Total revenue from operations | 117865 | 105091 | 105126 | 438807 | 417761 |
| 2 | Other income | 931 | 950 | 836 | 4053 | 3782 |
| 3 | Total income (1+2) | 118796 | 106041 | 105962 | 442860 | 421543 |
| 4 | Expenses | | | | | |
| | a) Cost of materials consumed | 59738 | 51038 | 48113 | 210462 | 205028 |
| | b) Purchases of stock-in-trade | 4439 | 4165 | 3219 | 14904 | 5681 |
| | c) Changes in inventories of finished goods, stock-in-trade and work-in progress | (2301) | 403 | 1962 | 4111 | 18 |
| | d) Employee benefits expense | 10628 | 10360 | 9600 | 42561 | 41805 |
| | e) Finance costs | 1181 | 1246 | 1391 | 4912 | 5564 |
| | f) Depreciation and amortisation expenses | 4837 | 4504 | 3939 | 17548 | 15763 |
| | g) Other expenses: | | | | | |
| | - Power and fuel expense | 10824 | 10300 | 10428 | 41783 | 46354 |
| | - Others | 18277 | 16178 | 17135 | 68282 | 66967 |
| | Total expenses | 107623 | 98194 | 95787 | 404563 | 387180 |
| 5 | Profit before share of profit/(loss) of an associate and exceptional items (3-4) | 11173 | 7847 | 10175 | 38297 | 34363 |
| 6 | Share of (loss)/profit of an associate | (2) | (2) | 3 | (18) | (2) |
| 7 | Profit before exceptional items and tax (5+6) | 11171 | 7845 | 10178 | 38279 | 34361 |
| 8 | Exceptional items (refer note 8) | - | (1304) | - | (1304) | - |
| 9 | Profit before tax (7+8) | 11171 | 6541 | 10178 | 36975 | 34361 |
| 10 | Tax expense | | | | | |
| | - Current tax | 2748 | 1824 | 2528 | 8423 | 8527 |
| | - Deferred tax (credit)/charge | (221) | 27 | 245 | 761 | 717 |
| 11 | Net profit for the period/year (9-10) | 8644 | 4690 | 7405 | 27791 | 25117 |
| 12 | Other comprehensive income (OCI) | | | | | |
| | i) a) Items that will not be reclassified to profit or loss | (391) | (117) | 94 | 87 | (183) |
| | b) Income tax relating to items that will not be reclassified to profit or loss | 54 | (14) | (29) | (13) | 57 |
| | ii) a) Items that will be reclassified to profit or loss | 736 | 262 | 505 | 2617 | 405 |
| | b) Income tax relating to items that will be reclassified to profit or loss | (185) | (66) | 30 | (659) | (101) |
| 13 | Total comprehensive income for the period/year (11+12) | 8858 | 4755 | 8005 | 29823 | 25295 |
| | Net profit attributable to: | | | | | |
| | Owners of the Company | 8644 | 4690 | 7405 | 27791 | 25117 |
| | Non-controlling interests | - | - | - | - | - |
| | Other comprehensive income attributable to: | | | | | |
| | Owners of the Company | 214 | 65 | 600 | 2032 | 178 |
| | Non-controlling interests | - | - | - | - | - |
| | Total comprehensive income attributable to: | | | | | |
| | Owners of the Company | 8858 | 4755 | 8005 | 29823 | 25295 |
| | Non-controlling interests | - | - | - | - | - |
| 14 | Earnings per share of ₹ 1 each (not annualised for the quarters) | | | | | |
| | Basic (₹) | 5.47 | 2.97 | 4.69 | 17.59 | 15.89 |
| | Diluted (₹) | 5.39 | 2.97 | 4.64 | 17.51 | 15.84 |
| 15 | Paid-up equity share capital (face value per share ₹ 1) | 1577 | 1580 | 1581 | 1577 | 1581 |
| 16 | Reserves excluding revaluation reserves (other equity) | | | | 311045 | 291127 |
| | See accompanying notes to the Consolidated Audited Financial Results | | | | | |



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Statement of Consolidated Audited Assets and Liabilities

(₹ in Lakhs)

| Sr. No. | Particulars | As at | As at |
|----------|--|---------------|---------------|
| | | 31 March | 31 March |
| | | (Audited) | (Audited) |
| | | 2026 | 2025 |
| A | ASSETS | | |
| 1. | Non-current assets | | |
| | Property, plant and equipment | 310362 | 251585 |
| | Capital work-in-progress | 15394 | 52518 |
| | Goodwill | 613 | - |
| | Other intangible assets | 2889 | 2318 |
| | Right of use assets | 4479 | 4194 |
| | Investments accounted for using the equity method | 677 | 639 |
| | Financial assets | | |
| | Investments | 2639 | 1411 |
| | Loans | 38 | 38 |
| | Other financial assets | 1267 | 373 |
| | Deferred tax assets (net) | 1420 | 1664 |
| | Income-tax assets (net) | 1387 | 776 |
| | Other non-current assets | 2570 | 2338 |
| | Total non-current assets | 343735 | 317854 |
| 2. | Current assets | | |
| | Inventories | 87996 | 94342 |
| | Financial assets | | |
| | Investments | - | 1621 |
| | Trade receivables | 78254 | 60713 |
| | Cash and cash equivalents | 18847 | 6936 |
| | Other bank balances | 146 | 2937 |
| | Loans | 43 | 32 |
| | Other financial assets | 4509 | 3862 |
| | Income-tax assets (net) | - | 312 |
| | Other current assets | 14843 | 14568 |
| | Total current assets | 204638 | 185323 |
| | Total assets | 548373 | 503177 |
| B | EQUITY AND LIABILITIES | | |
| 1. | Equity | | |
| | Equity share capital | 1577 | 1581 |
| | Other equity | 311045 | 291127 |
| | Total equity attributable to equity shareholders | 312622 | 292708 |
| 2. | Liabilities | | |
| | Non-current liabilities | | |
| | Financial liabilities | | |
| | Borrowings | 32211 | 36322 |
| | Lease liabilities | 763 | 505 |
| | Other financial liabilities | 12126 | 4377 |
| | Provisions | 7281 | 6654 |
| | Deferred tax liabilities (net) | 24199 | 22511 |
| | Total non-current liabilities | 76580 | 70369 |
| | Current liabilities | | |
| | Financial liabilities | | |
| | Borrowings | 45888 | 39331 |
| | Lease liabilities | 319 | 220 |
| | Trade payables | | |
| | Total outstanding dues of micro enterprises and small enterprises | 4861 | 2600 |
| | Total outstanding dues of creditors other than micro enterprises and small enterprises | 89204 | 78893 |
| | Other financial liabilities | 12960 | 12485 |
| | Other current liabilities | 2354 | 1576 |
| | Provisions | 2305 | 2104 |
| | Current tax liabilities (net) | 1280 | 2891 |
| | Total current liabilities | 159171 | 140100 |
| | Total equity and liabilities | 548373 | 503177 |



SIGNED FOR IDENTIFICATION PURPOSES



Jubilant Ingrevia Limited
Note1: Statement of Consolidated Audited Cash Flows

(₹ in Lakhs)

| Particulars | Year Ended | |
|---|----------------|----------------|
| | 31 March | 31 March |
| | (Audited) | (Audited) |
| | 2026 | 2025 |
| A. Cash flows from operating activities | | |
| Profit before tax | 36975 | 34361 |
| Adjustments: | | |
| Depreciation and amortisation expenses | 17548 | 15763 |
| Loss on sale, disposal, discard of property, plant and equipment (net) | 95 | 26 |
| Finance costs | 4912 | 5564 |
| Share-based payment expense | 1068 | 1214 |
| Unrealised foreign exchange loss/(gain) (net) | 832 | (177) |
| Interest income | (149) | (285) |
| Profit on sale of current investments | (24) | - |
| Share of loss of an associate | 18 | 2 |
| Excess provisions written back | (10) | (34) |
| Allowance for expected credit loss on trade receivables | 89 | 53 |
| | 24379 | 22126 |
| Operating cash flows before working capital changes | 61354 | 56487 |
| Increase in loans, other financial and non-financial assets | (812) | (65) |
| Increase in trade receivables | (16808) | (3677) |
| Decrease/(increase) in inventories | 6503 | (211) |
| Increase in other financial liabilities, other current liabilities and provisions | 1781 | 1373 |
| Increase in trade payables | 10742 | 4859 |
| Cash generated from operations | 62760 | 58766 |
| Income tax paid (net of refund) | (10333) | (7957) |
| Net cash generated from operating activities | 52427 | 50809 |
| B. Cash flows from investing activities | | |
| Purchase of property, plant and equipment and intangible assets (including capital work-in-progress, capital creditors and capital advances) | (29936) | (36578) |
| Proceeds from sale of property, plant and equipment | 984 | 1361 |
| Cash consideration paid for acquisition of subsidiary (net of deferred consideration) | (1125) | - |
| Investment in an associate | (205) | (769) |
| Investment in equity instruments | (1148) | (257) |
| Movement in current investments (net) | 1645 | (1621) |
| Movement in other bank balances (net) | 2103 | (1739) |
| Interest received | 89 | 323 |
| Net cash used in investing activities | (27593) | (39280) |
| C. Cash flows from financing activities | | |
| Acquisition of treasury shares by Jubilant Ingrevia Employee Welfare Trust | (3215) | - |
| Proceeds from sale of equity shares by Jubilant Ingrevia Employee Welfare Trust on exercise of stock options | 210 | 438 |
| Proceeds from non-current borrowings | 7600 | 2700 |
| Repayment of non-current borrowings | (8936) | (2443) |
| Proceeds from current borrowings (net) | 3389 | 2095 |
| Payment of principal portion of lease liabilities | (358) | (332) |
| Dividend paid | (7925) | (7977) |
| Finance costs paid (including interest on lease liabilities) | (6312) | (7357) |
| Net cash used in financing activities | (15547) | (12876) |
| D. Effect of exchange rate changes | 2617 | 405 |
| Net increase/(decrease) in cash and cash equivalents (A+B+C+D) | 11904 | (942) |
| Add: cash and cash equivalents at the beginning of the year | 6936 | 7878 |
| Add: cash and cash equivalents of the subsidiary acquired during the year (refer note below) | 7 | - |
| Cash and cash equivalents at the end of the year | 18847 | 6936 |

Note: This is the acquisition date balance of cash and cash equivalents of the subsidiary acquired during the year.



**SIGNED FOR
IDENTIFICATION
PURPOSES**



| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|----------|---|---------------|---------------|---------------|---------------|---------------|
| | | 31 March | 31 December | 31 March | 31 March | 31 March |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | | 2026 | 2025 | 2025 | 2026 | 2025 |
| 1 | Segment revenue | | | | | |
| | a. Speciality Chemicals | 60367 | 53818 | 55198 | 221426 | 206098 |
| | b. Nutrition & Health Solutions | 23028 | 20081 | 18968 | 79040 | 74797 |
| | c. Chemical Intermediates | 43452 | 39476 | 37833 | 166798 | 162166 |
| | Total | 126847 | 113375 | 111999 | 467264 | 443061 |
| | Less : Inter segment revenue | 8982 | 8284 | 6873 | 28457 | 25300 |
| | Total revenue from operations | 117865 | 105091 | 105126 | 438807 | 417761 |
| | a. Speciality Chemicals | 51590 | 45757 | 48650 | 193650 | 181797 |
| | b. Nutrition & Health Solutions | 22996 | 20068 | 18959 | 78970 | 74734 |
| | c. Chemical Intermediates | 43279 | 39266 | 37517 | 166187 | 161230 |
| | Total | 117865 | 105091 | 105126 | 438807 | 417761 |
| 2 | Segment results (profit before tax and interest) | | | | | |
| | a. Speciality Chemicals | 11293 | 9085 | 10657 | 41038 | 32976 |
| | b. Nutrition & Health Solutions | 2579 | 1702 | 2491 | 7942 | 8721 |
| | c. Chemical Intermediates | 551 | 48 | (191) | 1891 | 5940 |
| | Total | 14423 | 10835 | 12957 | 50871 | 47637 |
| | Less: i. Interest (finance costs) | 1181 | 1246 | 1391 | 4912 | 5564 |
| | ii. Un-allocable expenditure (net of un-allocable income) | 2071 | 1744 | 1388 | 7680 | 7712 |
| | iii. Exceptional Item - One Time impact of New Labour Codes | - | 1304 | - | 1304 | - |
| | Profit before tax | 11171 | 6541 | 10178 | 36975 | 34361 |
| 3 | Segment assets | | | | | |
| | a. Speciality Chemicals | 295402 | 289380 | 280979 | 295402 | 280979 |
| | b. Nutrition & Health Solutions | 80308 | 77274 | 72306 | 80308 | 72306 |
| | c. Chemical Intermediates | 143884 | 135844 | 135111 | 143884 | 135111 |
| | d. Unallocable corporate assets | 28779 | 25478 | 14781 | 28779 | 14781 |
| | Total segment assets | 548373 | 527976 | 503177 | 548373 | 503177 |
| 4 | Segment liabilities | | | | | |
| | a. Speciality Chemicals | 64627 | 62375 | 60783 | 64627 | 60783 |
| | b. Nutrition & Health Solutions | 14686 | 10202 | 11028 | 14686 | 11028 |
| | c. Chemical Intermediates | 53017 | 48130 | 36380 | 53017 | 36380 |
| | d. Unallocable corporate liabilities | 103421 | 97939 | 102278 | 103421 | 102278 |
| | Total segment liabilities | 235751 | 218646 | 210469 | 235751 | 210469 |



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Note 3: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

(Consolidated)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|---|---------------|-------------|-----------|------------|-----------|
| | | 31 March | 31 December | 31 March | 31 March | 31 March |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | | 2026 | 2025 | 2025 | 2026 | 2025 |
| 1 | Debt service coverage ratio (in times) # <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> <i>{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}</i> | 4.68 | 3.64 | 5.94 | 4.39 | 6.96 |
| 2 | Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i> | 14.55 | 10.91 | 11.16 | 12.36 | 10.01 |
| 3 | Bad debts to account receivable ratio (%) # <i>Definition: Bad debts/average of opening and closing trade receivables</i> <i>{Bad debts: Impairment balance as per statements of profit and loss}</i> | 0.03% | 0.05% | 0.02% | 0.11% | 0.03% |
| 4 | Debtors turnover (in times) # <i>Definition: Revenue from operations/average of opening and closing trade receivables</i> | 1.60 | 1.44 | 1.75 | 6.32 | 7.09 |
| 5 | Inventory turnover (in times) # <i>Definition: Cost of goods sold/average of opening and closing inventories</i> | 0.72 | 0.63 | 0.56 | 2.52 | 2.24 |
| 6 | Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> <i>{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses}</i> <i>{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}</i> | 9.69% | 7.80% | 10.21% | 8.92% | 8.65% |
| 7 | Net profit margin (%) <i>Definition: Net profit/total income</i> | 7.28% | 4.42% | 6.99% | 6.28% | 5.96% |
| 8 | Net worth (In ₹ Lakhs) <i>{Net worth: Equity share capital + other equity}</i> | 312622 | 309330 | 292708 | 312622 | 292708 |
| 9 | Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> <i>{Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}</i> | 0.19 | 0.18 | 0.22 | 0.19 | 0.22 |
| 10 | Current ratio (in times) <i>Definition: Current assets/current liabilities</i> | 1.29 | 1.37 | 1.32 | 1.29 | 1.32 |
| 11 | Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> <i>{Long term debt: Long term borrowings (gross of transaction costs)}</i> <i>{working capital: Current assets - current liabilities}</i> | 0.71 | 0.66 | 0.80 | 0.71 | 0.80 |
| 12 | Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i> | 0.68 | 0.64 | 0.67 | 0.68 | 0.67 |
| 13 | Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> <i>{Total debts: Long term borrowings (gross of transaction costs) + short term borrowings}</i> | 0.14 | 0.14 | 0.15 | 0.14 | 0.15 |

not annualised for the quarters.



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Notes to consolidated audited financial results (cont'd):

4. These consolidated audited financial results have been prepared in accordance with recognition and measurement principles laid down in Ind AS as prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) read with SEBI Circular SEBI/HO/DDHS/DDHS PoD/P/CIR/2025/0000000137 dated 15 October 2025.
5. The Group comprises of the following components:

| Name | Relationship with the Holding Company |
|---|---|
| Jubilant Infrastructure Limited | Subsidiary |
| Jubilant Agro Science Limited | Subsidiary |
| Jubilant Ingrevia (USA) Inc. (formally known as Jubilant Life Science (USA) Inc.) | Subsidiary |
| Jubilant Life Sciences NV | Subsidiary |
| Jubilant Ingrevia International Pte. Limited (formally known as Jubilant Life Sciences International Pte. Limited) | Subsidiary |
| Jubilant Life Sciences (Shanghai) Limited | Subsidiary |
| Jubilant Ingrevia Employee Welfare Trust | Subsidiary |
| Remidex Pharma Private Limited | Subsidiary (with effect from 30 March 2026) |
| Mister Veg Foods Private Limited | Associate |
| AMP Energy Green Fifteen Private Limited | Associate |
| O2 Renewable Energy XVIII Private Limited | Associate (with effect from 25 April 2025) |

6. The Board of Directors at its meeting held on 26 May 2026 has recommended a final dividend of ₹ 2.5 per equity share of (₹1 each) amounting to ₹ 3982 lakhs for the year ended 31 March 2026 subject to approval in Annual General Meeting. During the quarter ended 31 December 2025, the Holding Company has already declared an interim dividend of ₹ 2.5 per equity share of (₹1 each) and hence, the total dividend for the year ended 31 March 2026 is amounting to be ₹ 7964 lakhs i.e. ₹ 5 per equity share of (₹ 1 each).
7. During the quarter, the Holding Company has allotted 9469 equity shares on exercise of vested stock options by eligible employees.
8. During the year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits primarily due to change in definition of 'wages' under these Codes. Based on the currently available information, the Group has assessed the impact of these changes in accordance with Ind AS 19 – Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefit expense of ₹ 1304 lakhs, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. Subsequently, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Group is currently evaluating the consequential impact of these Rules. The Group continues to monitor developments pertaining to the Labour Codes and would provide appropriate accounting impact on the basis of such developments as needed.
9. During the quarter, the Holding Company has acquired 100% stake of Remidex Pharma Private Limited along with their customer related intangibles under Share Purchase Agreement with effect from 30 March 2026, for a purchase consideration of ₹ 1,628 lakhs. The said business acquisition will enable the Holding Company to move forward in the value chain towards premises in human nutrition and pharmaceutical manufacturing.
10. The figures for the quarter ended 31 March 2026 and quarter ended 31 March 2025, as reported in the consolidated financial results, are the balancing figures between the audited figures for the year ended 31 March 2026 and 31 March 2025 and the published year to date figures for 31 December 2025 and 31 December 2024, which were subjected to limited review by the statutory auditors.
11. Previous periods figures have been regrouped/reclassified, wherever necessary. The impact of such reclassification/regrouping is not material to the financial results.
12. The above consolidated audited financial results were reviewed by the Audit Committee on 25 May 2026 and approved by the Board of Directors at its meeting held on 26 May 2026. The audit report of the Statutory Auditors is being filed with the BSE Limited and the National Stock Exchange Limited of India. For more details on consolidated audited results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

Place : Noida
Date : 26 May 2026



**SIGNED FOR
IDENTIFICATION
PURPOSES**



For Jubilant Ingrevia Limited


Deepak Jain
CEO & Managing Director

Walker Chandiook & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram- 122002
India
T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Report on Standalone Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), including SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025.
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations; and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India



Walker Chandiook & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Responsibilities of Management and Those Charged with Governance for the Statement

4. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 and Regulation 52(4) of the Listing Regulations including SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;



Walker Chandiook & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of Jubilant Ingrevia Limited Pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended 31 March 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No.: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani
Partner
Membership No. 517440



UDIN: 26517440VHWUJJ5536

Place: Gurugram
Date: 26 May 2026

Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Standalone Audited Financial Results for the Quarter and Year Ended 31 March 2026

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|-----------|--|---------------|---------------|---------------|---------------|---------------|
| | | 31 March | 31 December | 31 March | 31 March | 31 March |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | | 2026 | 2025 | 2025 | 2026 | 2025 |
| 1 | Revenue from operations | | | | | |
| | a) Sales/Income from operations | 108131 | 100843 | 95240 | 409745 | 388095 |
| | b) Other operating income | 1216 | 950 | 1958 | 4104 | 6028 |
| | Total revenue from operations | 109347 | 101793 | 97198 | 413849 | 394123 |
| 2 | Other income | 4603 | 3196 | 3560 | 9969 | 8101 |
| 3 | Total income (1+2) | 113950 | 104989 | 100758 | 423818 | 402224 |
| 4 | Expenses | | | | | |
| | a) Cost of materials consumed | 59722 | 52530 | 49637 | 215457 | 205975 |
| | b) Purchases of stock-in-trade | 2856 | 3139 | 3206 | 12288 | 5668 |
| | c) Changes in inventories of finished goods, stock-in-trade and work-in-progress | (2933) | 1070 | (1052) | 2104 | (2851) |
| | d) Employee benefits expense | 9179 | 8943 | 8625 | 37295 | 37607 |
| | e) Finance costs | 1314 | 1455 | 1574 | 5662 | 6507 |
| | f) Depreciation and amortisation expenses | 4284 | 4158 | 3679 | 16118 | 14732 |
| | g) Other expenses: | | | | | |
| | - Power and fuel expense | 11804 | 11079 | 10645 | 44321 | 47772 |
| | - Others | 14948 | 13851 | 13349 | 55145 | 52478 |
| | Total expenses | 101174 | 96225 | 89663 | 388390 | 367888 |
| | Profit before exceptional items and tax (3-4) | 12776 | 8764 | 11095 | 35428 | 34336 |
| 6 | Exceptional items (refer note 7) | - | (1222) | - | (1222) | - |
| 7 | Profit before tax (5+6) | 12776 | 7542 | 11095 | 34206 | 34336 |
| 8 | Tax expense | | | | | |
| | - Current tax | 2189 | 1518 | 2246 | 6627 | 7271 |
| | - Deferred tax charge/(credit) | 65 | 53 | (138) | 782 | 723 |
| 9 | Net profit for the period/year (7-8) | 10522 | 5971 | 8987 | 26797 | 26342 |
| 10 | Other comprehensive income (OCI) | | | | | |
| | i) a) Items that will not be reclassified to profit or loss | 33 | (60) | 206 | 20 | (281) |
| | b) Income tax relating to items that will not be reclassified to profit or loss | (8) | 15 | (21) | (5) | 71 |
| | ii) a) Items that will be reclassified to profit or loss | - | - | - | - | - |
| | b) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - |
| 11 | Total comprehensive income for the period/year (9+10) | 10547 | 5926 | 9172 | 26812 | 26132 |
| 12 | Earnings per share of ₹ 1 each (not annualised for the quarters) | | | | | |
| | Basic (₹) | 6.60 | 3.75 | 5.64 | 16.82 | 16.54 |
| | Diluted (₹) | 6.60 | 3.75 | 5.64 | 16.82 | 16.54 |
| 13 | Paid-up equity share capital (face value per share ₹ 1) | 1593 | 1593 | 1593 | 1593 | 1593 |
| 14 | Reserves excluding revaluation reserves (other equity) | | | | 262413 | 242495 |
| | See accompanying notes to the Standalone Audited Financial Results | | | | | |



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited
Statement of Standalone Audited Assets and Liabilities

(₹ in Lakhs)

| Sr. No. | Particulars | As at | As at |
|----------|--|---------------|---------------|
| | | 31 March | 31 March |
| | | (Audited) | (Audited) |
| | | 2026 | 2025 |
| A | ASSETS | | |
| 1. | Non-current assets | | |
| | Property, plant and equipment | 229352 | 226024 |
| | Capital work-in-progress | 13860 | 19675 |
| | Intangible assets | 1528 | 1709 |
| | Right of use assets | 5770 | 5809 |
| | Financial assets | | |
| | Investments in subsidiaries and associates | 32657 | 30976 |
| | Loans | 4136 | 37 |
| | Other financial assets | 951 | 253 |
| | Income-tax assets (net) | 1207 | 606 |
| | Other non-current assets | 1963 | 1273 |
| | Total non-current assets | 291424 | 286362 |
| 2. | Current assets | | |
| | Inventories | 73256 | 80437 |
| | Financial assets | | |
| | Trade receivables | 68879 | 57327 |
| | Cash and cash equivalents | 16467 | 4107 |
| | Other bank balances | 134 | 978 |
| | Loans | 32 | 1125 |
| | Other financial assets | 7579 | 8389 |
| | Other current assets | 14559 | 13347 |
| | Total current assets | 180906 | 165710 |
| | Total assets | 472330 | 452072 |
| B | EQUITY AND LIABILITIES | | |
| 1. | Equity | | |
| | Equity share capital | 1593 | 1593 |
| | Other equity | 262413 | 242495 |
| | Total equity | 264006 | 244088 |
| 2. | Liabilities | | |
| | Non-current liabilities | | |
| | Financial liabilities | | |
| | Borrowings | 22536 | 34971 |
| | Lease liabilities | 3540 | 3382 |
| | Provisions | 6710 | 6287 |
| | Deferred tax liabilities (net) | 22768 | 21981 |
| | Total non-current liabilities | 55554 | 66621 |
| | Current liabilities | | |
| | Financial liabilities | | |
| | Borrowings | 47934 | 43581 |
| | Lease liabilities | 644 | 538 |
| | Trade payables | | |
| | Total outstanding dues of micro enterprises and small enterprises | 4289 | 2444 |
| | Total outstanding dues of creditors other than micro enterprises and small enterprises | 83335 | 77160 |
| | Other financial liabilities | 7311 | 6133 |
| | Other current liabilities | 6065 | 7010 |
| | Provisions | 2185 | 2023 |
| | Current tax liabilities (net) | 1007 | 2474 |
| | Total current liabilities | 152770 | 141363 |
| | Total equity and liabilities | 472330 | 452072 |



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited
Note1: Statement of Standalone Audited Cash Flows

(₹ in Lakhs)

| Particulars | Year Ended | |
|---|----------------|----------------|
| | 31 March | 31 March |
| | (Audited) | (Audited) |
| | 2026 | 2025 |
| A. Cash flows from operating activities | | |
| Profit before tax | 34206 | 34336 |
| Adjustments: | | |
| Depreciation and amortisation expenses | 16118 | 14732 |
| Loss on sale, disposal, discard of property, plant and equipment (net) | 98 | 18 |
| Finance costs | 5662 | 6507 |
| Share-based payment expense | 1068 | 1214 |
| Unrealised foreign exchange loss/(gain) (net) | 787 | (177) |
| Interest income | (274) | (202) |
| Dividend Income | (5876) | (4500) |
| Excess provisions written back | (10) | (34) |
| Allowance for expected credit loss on trade receivables | 89 | 52 |
| | 17662 | 17610 |
| Operating cash flows before working capital changes | 51868 | 51946 |
| Increase in loans, other financial and non-financial assets | (289) | (522) |
| Increase in trade receivables | (11169) | (1166) |
| Decrease/(increase) in inventories | 7181 | (2905) |
| Increase/(decrease) in other financial liabilities, other current liabilities and provisions | 526 | (222) |
| Increase in trade payables | 6772 | 4361 |
| Cash generated from operations | 54889 | 51492 |
| Income tax paid (net of refund) | (8695) | (7358) |
| Net cash generated from operating activities | 46194 | 44134 |
| B. Cash flows from investing activities | | |
| Purchase of property, plant and equipment and intangible assets (including capital work-in-progress, capital creditors and capital advances) | (13437) | (21626) |
| Proceeds from sale of property, plant and equipment | 711 | 1357 |
| Cash consideration paid for acquisition of subsidiary (net of deferred consideration) | (1118) | - |
| Investment in Subsidiary | - | (1150) |
| Investment in an associate | (205) | (769) |
| Loan given to subsidiary | (3000) | (1100) |
| Movement in other bank balances (net) | 143 | 222 |
| Interest received | 207 | 246 |
| Dividend received | 5876 | 1765 |
| Net cash used in investing activities | (10823) | (21055) |
| C. Cash flows from financing activities | | |
| Repayment of non-current borrowings | (8186) | (2443) |
| Repayment of non-current borrowings to subsidiary | (2650) | (4025) |
| Proceeds from current borrowings (net) | 2753 | 2095 |
| Payment of principal portion of lease liabilities | (403) | (396) |
| Dividend paid | (7918) | (7952) |
| Finance costs paid (including interest on lease liabilities) | (6607) | (8121) |
| Net cash used in financing activities | (23011) | (20842) |
| Net increase in cash and cash equivalents (A+B+C) | 12360 | 2237 |
| Add: cash and cash equivalents at the beginning of the year | 4107 | 1870 |
| Cash and cash equivalents at the end of the year | 16467 | 4107 |



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Note 2: Standalone Audited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Year Ended 31 March 2026

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|--|---------------|---------------|---------------|---------------|---------------|
| | | 31 March | 31 December | 31 March | 31 March | 31 March |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | | 2026 | 2025 | 2025 | 2026 | 2025 |
| 1 | Segment revenue | | | | | |
| | a. Speciality Chemicals | 57529 | 52715 | 52260 | 213992 | 200799 |
| | b. Nutrition & Health Solutions | 19396 | 19956 | 17256 | 72261 | 71240 |
| | c. Chemical Intermediates | 41404 | 37406 | 34555 | 156053 | 147384 |
| | Total | 118329 | 110077 | 104071 | 442306 | 419423 |
| | Less : Inter segment revenue | 8982 | 8284 | 6873 | 28457 | 25300 |
| | Total revenue from operations | 109347 | 101793 | 97198 | 413849 | 394123 |
| | a. Speciality Chemicals | 48752 | 44654 | 45712 | 186216 | 176498 |
| | b. Nutrition & Health Solutions | 19364 | 19943 | 17247 | 72191 | 71177 |
| | c. Chemical Intermediates | 41231 | 37196 | 34239 | 155442 | 146448 |
| | Total | 109347 | 101793 | 97198 | 413849 | 394123 |
| 2 | Segment results (profit before tax, exceptional items and interest) | | | | | |
| | a. Speciality Chemicals | 15398 | 12061 | 12292 | 47789 | 35589 |
| | b. Nutrition & Health Solutions | 864 | 671 | 1701 | 3037 | 8052 |
| | c. Chemical Intermediates | (155) | (803) | 132 | (2173) | 5007 |
| | Total | 16107 | 11929 | 14125 | 48653 | 48648 |
| | Less: i. Interest (finance costs) | 1314 | 1455 | 1574 | 5662 | 6507 |
| | ii. Un-allocable expenditure (net of un-allocable income) | 2017 | 1710 | 1456 | 7563 | 7805 |
| | iii. Exceptional item - One Time impact of New Labour Codes | | 1222 | - | 1222 | - |
| | Profit before tax | 12776 | 7542 | 11095 | 34206 | 34336 |
| 3 | Segment assets | | | | | |
| | a. Speciality Chemicals | 232316 | 232003 | 243167 | 232316 | 243167 |
| | b. Nutrition & Health Solutions | 61493 | 58439 | 54410 | 61493 | 54410 |
| | c. Chemical Intermediates | 124896 | 117526 | 115324 | 124896 | 115324 |
| | d. Unallocable corporate assets | 53625 | 48777 | 39171 | 53625 | 39171 |
| | Total segment assets | 472330 | 456745 | 452072 | 472330 | 452072 |
| 4 | Segment liabilities | | | | | |
| | a. Speciality Chemicals | 42659 | 44438 | 52919 | 42659 | 52919 |
| | b. Nutrition & Health Solutions | 15300 | 12733 | 12379 | 15300 | 12379 |
| | c. Chemical Intermediates | 55025 | 49652 | 38614 | 55025 | 38614 |
| | d. Unallocable corporate liabilities | 95340 | 92702 | 104072 | 95340 | 104072 |
| | Total segment liabilities | 208324 | 199525 | 207984 | 208324 | 207984 |



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Note 3: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

(Standalone)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|---|-----------------------|----------------------------|-----------------------|-----------------------|-----------------------|
| | | 31 March (Audited) | 31 December (Unaudited) | 31 March (Audited) | 31 March (Audited) | 31 March (Audited) |
| | | 2026 | 2025 | 2025 | 2026 | 2025 |
| 1 | Debt service coverage ratio (in times)# <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> <i>{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}</i> | 5.08 | 3.83 | 5.85 | 4.13 | 6.21 |
| 2 | Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i> | 13.98 | 9.88 | 10.39 | 10.10 | 8.54 |
| 3 | Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> <i>{Bad debts: Impairment balance as per statements of profit and loss}</i> | 0.03% | 0.05% | 0.03% | 0.12% | 0.03% |
| 4 | Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i> | 1.65 | 1.53 | 1.67 | 6.56 | 6.94 |
| 5 | Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i> | 0.84 | 0.75 | 0.64 | 2.99 | 2.64 |
| 6 | Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> <i>{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses}</i> <i>{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}</i> | 8.68% | 6.95% | 9.37% | 7.52% | 8.31% |
| 7 | Net profit margin (%) <i>Definition: Net profit/total income</i> | 9.24% | 5.69% | 8.92% | 6.32% | 6.55% |
| 8 | Net worth (In ₹ Lakhs) <i>{Net worth: Equity share capital + other equity}</i> | 264006 | 257220 | 244088 | 264006 | 244088 |
| 9 | Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> <i>{Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}</i> | 0.20 | 0.21 | 0.30 | 0.20 | 0.30 |
| 10 | Current ratio (in times) <i>Definition: Current assets/current liabilities</i> | 1.18 | 1.23 | 1.17 | 1.18 | 1.17 |
| 11 | Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> <i>{Long term debt: Long term borrowings (gross of transaction costs)}</i> <i>{working capital: Current assets - current liabilities}</i> | 0.80 | 0.87 | 1.44 | 0.80 | 1.44 |
| 12 | Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i> | 0.73 | 0.69 | 0.68 | 0.73 | 0.68 |
| 13 | Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> <i>{Total debts: Long term borrowings (gross of transaction costs) + short term borrowings}</i> | 0.15 | 0.15 | 0.17 | 0.15 | 0.17 |

not annualised for the quarters.



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Notes to standalone audited financial results (cont'd):

4. These standalone audited financial results have been prepared in accordance with recognition and measurement principles laid down Ind AS as prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) read with SEBI Circular SEBI/HO/DDHS/DDHS PoD/P/CIR/2025/0000000137 dated 15 October 2025.
5. The Board of Directors at its meeting held on 26 May 2026 has recommended a final dividend of ₹ 2.5 per equity share of (₹1 each) amounting to ₹ 3982 lakhs for the year ended 31 March 2026 subject to approval in Annual General Meeting. During the quarter ended 31 December 2025, the Company has already declared an interim dividend of ₹ 2.5 per equity share of (₹1 each) and hence, the total dividend for the year ended 31 March 2026 is amounting to be ₹ 7964 lakhs i.e. ₹ 5 per equity share of (₹ 1 each).
6. During the quarter, the Company has allotted 9469 equity shares on exercise of vested stock options by eligible employees.
7. During the year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits primarily due to change in definition of 'wages' under these Codes. Based on the currently available information, the Company has assessed the impact of these changes in accordance with Ind AS 19 – Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefits expense of ₹ 1222 lakhs, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. Subsequently, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Company is currently evaluating the consequential impact of these Rules. The Company continues to monitor developments pertaining to the Labour Codes and would provide appropriate accounting impact on the basis of such developments as needed.
8. During the quarter, the Company has acquired 100% stake of Remidex Pharma Private Limited under Share Purchase Agreement with effect from 30 March 2026, for a purchase consideration of ₹ 1,628 lakhs. The said business acquisition will enable the Company to move forward in the value chain towards premixes in human nutrition and pharmaceutical manufacturing.
9. The figures for the quarter ended 31 March 2026 and quarter ended 31 March 2025, as reported in standalone financial results, are balancing figures between the audited figures for the year ended 31 March 2026 and 31 March 2025 and the published year to date figures for 31 December 2025 and 31 December 2024, which were subject to limited review by the statutory auditors.
10. Previous periods figures have been regrouped/reclassified, wherever necessary. The impact of such reclassification/regrouping is not material to the financial results.
11. The above standalone audited financial results were reviewed by the Audit Committee on 25 May 2026 and approved by the Board of Directors at its meeting held on 26 May 2026. The audit report of the Statutory Auditors is being filed with the BSE Limited and the National Stock Exchange Limited of India. For more details on standalone audited results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

Place : Noida
Date : 26 May 2026



**SIGNED FOR
IDENTIFICATION
PURPOSES**



For Jubilant Ingrevia Limited


Deepak Jain
CEO & Managing Director



JUBILANT INGREVIA

May 26, 2026

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Subject: Declaration pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, (SEBI Listing Regulations)

Dear Sir/Madam,

Pursuant to Regulation 33 of the SEBI Listing Regulations, we hereby state that the Statutory Auditors of the Company i.e. M/s Walker Chandiook & Co. LLP, Chartered Accountants (Firm Registration Number 001076N/N500013) have issued an Auditor's Report with unmodified opinion on the Audited Financial Results of the Company (Standalone and Consolidated) for the financial year ended March 31, 2026.

We request you to take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Varun Gupta
Chief Financial Officer

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657